These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1152 related items for PubMed ID: 26124162

  • 1. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
    Smith JR, Barber KE, Hallesy J, Raut A, Rybak MJ.
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
    [Abstract] [Full Text] [Related]

  • 2. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
    Mirza HC, Sancak B, Gür D.
    Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019
    [Abstract] [Full Text] [Related]

  • 3. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin.
    Sader HS, Fritsche TR, Jones RN.
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2330-6. PubMed ID: 16801409
    [Abstract] [Full Text] [Related]

  • 4. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
    Sader HS, Flamm RK, Jones RN.
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3178-81. PubMed ID: 23629712
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
    Barber KE, Smith JR, Raut A, Rybak MJ.
    J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Leonard SN, Rybak MJ.
    J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
    [Abstract] [Full Text] [Related]

  • 7. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.
    Farrell DJ, Flamm RK, Sader HS, Jones RN.
    Int J Antimicrob Agents; 2014 Apr; 43(4):323-7. PubMed ID: 24411474
    [Abstract] [Full Text] [Related]

  • 8. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR, Yim J, Raut A, Rybak MJ.
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey.
    Sancak B, Yagci S, Gür D, Gülay Z, Ogunc D, Söyletir G, Yalcin AN, Dündar DO, Topçu AW, Aksit F, Usluer G, Ozakin C, Akalin H, Hayran M, Korten V.
    BMC Infect Dis; 2013 Dec 10; 13():583. PubMed ID: 24325260
    [Abstract] [Full Text] [Related]

  • 11. [Investigation of antibiotic resistance patterns and reduced vancomycin susceptibilities of methicillin-resistant Staphylococcus aureus isolates: a multi-center study].
    Çıkman A, Aydın M, Gülhan B, Parlak M, Gültepe B, Kalaycı Y, Bayındır Bilmen F, Solmaz S, Özekinci T.
    Mikrobiyol Bul; 2015 Apr 10; 49(2):240-8. PubMed ID: 26167824
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
    Barber KE, Smith JR, Ireland CE, Boles BR, Rose WE, Rybak MJ.
    Antimicrob Agents Chemother; 2015 Aug 10; 59(8):4497-503. PubMed ID: 25987623
    [Abstract] [Full Text] [Related]

  • 13. Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus.
    Xiong YQ, Hady WA, Bayer AS, Chen L, Kreiswirth BN, Yang SJ.
    Antimicrob Agents Chemother; 2012 Nov 10; 56(11):5528-33. PubMed ID: 22890759
    [Abstract] [Full Text] [Related]

  • 14. Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.
    Smith JR, Arya A, Yim J, Barber KE, Hallesy J, Singh NB, Rybak MJ.
    Antimicrob Agents Chemother; 2016 Jul 10; 60(7):3970-5. PubMed ID: 27090172
    [Abstract] [Full Text] [Related]

  • 15. In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides.
    Capone A, Cafiso V, Campanile F, Parisi G, Mariani B, Petrosillo N, Stefani S.
    Eur J Clin Microbiol Infect Dis; 2016 Apr 10; 35(4):625-31. PubMed ID: 26815434
    [Abstract] [Full Text] [Related]

  • 16. In vitro activity of daptomycin and comparator agents against Staphylococcus aureus isolates from intravenous drug users with right endocarditis.
    Sanchez-Porto A, Casanova-Roman M, Casas-Ciria J, Santaella MJ, Sanchez-Morenilla I, Eiros-Bouza JM.
    Infez Med; 2010 Jun 10; 18(2):108-12. PubMed ID: 20610933
    [Abstract] [Full Text] [Related]

  • 17. In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus.
    Saravolatz LD, Pawlak J, Johnson L, Bonilla H, Saravolatz LD, Fakih MG, Fugelli A, Olsen WM.
    Antimicrob Agents Chemother; 2012 Aug 10; 56(8):4478-82. PubMed ID: 22585222
    [Abstract] [Full Text] [Related]

  • 18. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Jevitt LA, Smith AJ, Williams PP, Raney PM, McGowan JE, Tenover FC.
    Microb Drug Resist; 2003 Aug 10; 9(4):389-93. PubMed ID: 15000746
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed ME, Vidaillac C, Rybak MJ.
    Antimicrob Agents Chemother; 2012 Feb 10; 56(2):955-9. PubMed ID: 22123693
    [Abstract] [Full Text] [Related]

  • 20. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of Staphylococcus aureus in a Simulated Pharmacodynamic/Pharmacokinetic Model.
    Kebriaei R, Rice SA, Stamper KC, Rybak MJ.
    Antimicrob Agents Chemother; 2019 Apr 10; 63(4):. PubMed ID: 30670436
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.